Aug. 16, 2017 Price forecast | 2 weeks: 2.61% | 1 month: 1.18% | 3 months: -0.59%

EGRX stock forecast

Our latest prediction for Eagle Pharmaceuticals, Inc.'s stock price was made on the Aug. 16, 2017 when the stock price was at 55.77$.

In the short term (2weeks), EGRX's stock price should outperform the market by 2.61%. During that period the price should oscillate between -7.79% and +13.29%.

In the medium term (3months), EGRX's stock price should underperform the market by -0.59%. During that period the price should oscillate between -18.49% and +34.44%.

About Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

At the moment the company generates 204M USD in revenues.

On its last earning announcement, the company reported a profit of 1.84$ per share.

The book value per share is 12.34$

Eagle Pharmaceuticals, Inc. website

Three months stock forecastAug. 16, 2017


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
204M 72.00% 41M 19.89% 28M 1.84 - - 16M 12.34 40M -3M 37M